Total funding in the healthtech, life sciences and healthcare space in May 2024 was $261 million. The funding saw a dip by 69.2 per cent when compared to April 2024. However, the funding has surged by 379.8 per cent when compared with the $54.4 million raised in May 2023.
In terms of stagewise funding, the majority – 85 per cent of the funding in May 2024 came from late-stage investments, followed by PE at 7.7 per cent, early-stage at 4.7 per cent and seed-stage at 2.2 per cent.
Maiva Pharma, NephroPlus and Orbicular Pharmaceutical reported the biggest deals of May 2024. Bessemer Venture Partners, Legacy Assets and Venture Catalysts were the most active investors during the period.